ONVO earnings call for the period ending December 31, 2018.
News & Analysis: Organovo Holdings
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
Shares dropped after the company reported uninspiring fourth-quarter results.
Could the beaten-down 3D bioprinting stock face even worse days ahead?
Organovo Holdings' Q4 results and fiscal 2018 outlook show growth still isn't what it used to be.
If you're searching for stocks with jaw-dropping growth potential, these three names should be at the top of your list.